243 related articles for article (PubMed ID: 36154176)
81. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
Paterson SL; Barry PJ; Horsley AR
Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
[No Abstract] [Full Text] [Related]
82. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.
Keogh RH; Cosgriff R; Andrinopoulou ER; Brownlee KG; Carr SB; Diaz-Ordaz K; Granger E; Jewell NP; Lewin A; Leyrat C; Schlüter DK; van Smeden M; Szczesniak RD; Connett GJ
Thorax; 2022 Sep; 77(9):873-881. PubMed ID: 34556554
[TBL] [Abstract][Full Text] [Related]
83. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
[TBL] [Abstract][Full Text] [Related]
84. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
[TBL] [Abstract][Full Text] [Related]
85. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.
Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A
Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583
[TBL] [Abstract][Full Text] [Related]
86. A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment.
Bhaskaran D; Bateman K
J Cyst Fibros; 2022 Nov; 21(6):1077-1079. PubMed ID: 35840534
[TBL] [Abstract][Full Text] [Related]
87. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
[TBL] [Abstract][Full Text] [Related]
88. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
[TBL] [Abstract][Full Text] [Related]
89. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
Zaher A; ElSaygh J; Elsori D; ElSaygh H; Sanni A
Cureus; 2021 Jul; 13(7):e16144. PubMed ID: 34268058
[TBL] [Abstract][Full Text] [Related]
90. Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis.
Atkinson M; Johnson O; Wilson N; Walshaw M; FitzMaurice TS
J Cyst Fibros; 2022 Nov; 21(6):1070-1073. PubMed ID: 35752560
[TBL] [Abstract][Full Text] [Related]
91. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
92. Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.
Hong E; Shi A; Beringer P
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):203-216. PubMed ID: 37259485
[TBL] [Abstract][Full Text] [Related]
93. Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis.
Welsner M; Schulte T; Dietz-Terjung S; Weinreich G; Stehling F; Taube C; Strassburg S; Schoebel C; Sutharsan S
Respiration; 2022; 101(8):766-774. PubMed ID: 35598598
[TBL] [Abstract][Full Text] [Related]
94. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
95. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
96. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
[TBL] [Abstract][Full Text] [Related]
97. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
Habib AR; Kajbafzadeh M; Desai S; Yang CL; Skolnik K; Quon BS
Sci Rep; 2019 May; 9(1):7234. PubMed ID: 31076617
[TBL] [Abstract][Full Text] [Related]
98. Entering the era of highly effective modulator therapies.
Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
[TBL] [Abstract][Full Text] [Related]
99. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
100. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
